A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS
1. National Institutes of Health, Bethesda, MD 20892 and Centers for Disease Control and Prevention, Atlanta, GA 30305 are soliciting proposals from small business concerns that possess the research and edevelopment (R&D) expertise to conduct innovative research that will contribute toward meeting the program objectives of the agencies. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS 2018-1 with a closing date on or around October 20, 2017, for receipt of proposals, soon will be available electronically through the NIH Small Business Research Funding Opportunities (http://sbir.nih.gov) Web site and at fedbizopps.gov. The SBIR Phase I and Fast-Track Contract Solicitation will be available ONLY via electronic means. Printed copies of the Solicitation will not be distributed. Potential offerors are encouraged to check the NIH Small Business Research Funding Opportunities Web site and fedbizopps.gov for updates on the program. Any updates or corrections to the Solicitation will be posted there. The purposes of the SBIR program are to: (a) stimulate technological innovation in the private sector; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) increase the commercial application of Federally-supported research results; (d) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern AND (4) has, including its affiliates, no more than 500 employees.** Note: For purposes of the SBIR Program, this size standard is established by law, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702.Following are the research topics identified in the NIH/CDC SBIR Contract Solicitation PHS 2018-1: NATIONAL INSTITUTES OF HEALTH (NIH)NATIONAL CANCER INSTITUTE (NCI): Targeted Therapy for Cancer- and Cancer Therapy-Related Cachexia. Drugs to Exploit the Immune Response Generated by Radiation Therapy. Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics. Tools and Technologies for Monitoring RNA Modifications. Novel Approaches for Local Delivery of Chemopreventive Agents. Diagnostic Imaging for Cancer Immunotherapies. Imaging-Based Tools for Longitudinal and Multi-Dimensional Mapping of the Tumor and Its Microenvironment. Bridging the Guideline Implementation Gap: Clinical Decision-Support to Improve Cancer Symptom Management. Mobile Application for Surveillance of Post-Radiation Therapy Health-Related Quality of Life. Software Enabling Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients. Computer Aided Decision Support for Radiation Oncology. Development of Artificial Intelligence (AI) Tools to Understand and Duplicate Experts' Radiation Therapy Planning for Prostate Cancer. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI): Devices for Transcatheter Surgery. Tapered Guidewires for Transcatheter Electrosurgery. Reagent Development for Small Cell Number ChIC-seq. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Methods Improving HIV Protein Expression: Cell Substrate and Protein Purification. Inhaled Delivery of Clofazimine (CFZ) - An Important Anti-tuberculosis Drug. High-Throughput Assay Platform for Quantifying Latent HIV Reservoirs. Effective Targeted Delivery of RNA-based Vaccines and Therapeutics. Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases. Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases. Reagents for Immunologic Analysis of Non-mammalian Models. Development of Sample Sparing Assays. Bioinformatics tools to make data FAIR (Findable, Accessible, Interoperable, and Re-usable). Diagnostics to Enable Malaria and Neglected Tropical Diseases (NTDs) Elimination. Computational Software Development to Advance Translational Research for Infectious Diseases. Induction of Mucosal Immune Response to Parenterally Delivered Vaccines. Novel Vaccine Technologies and Strategies to Promote Sustained Vaccine Efficacy. NATIONAL INSTITUTE ON DRUG ABUSE (NIDA): Digital Markers for Marijuana Intoxication. Development of Portable Neuromodulatory Devices for the Treatment of Substance Use Disorders. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)CENTER FOR GLOBAL HEALTH (CGH): Improving Global Laboratory Diagnostic Capacity: Modular, End-user-assembled Biosafety Cabinets for Sustainable Biocontainment. NATIONAL CENTER FOR CHRONIC DISEASE AND HEALTH PROMOTION (NCCDPHP): Finding Human Carriers of Taeniasis to Prevent Neurocysticercosis Associated Epilepsy. Web-based Application to Enable Healthy Behaviors through Behavioral Design. NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASES (NCEZID): Antifungal-containing Solution for Corneal Tissue Storage and Transport. Bacterial Amplicon Subtyping. Identification of Brucella canis Seroreactive Proteins and Serology Assay Development. Multiplex Pan_lyssavirus/β-actin Real-time RT-PCR Assays for Rabies Diagnostics. Tools for Combined Analysis of Optical Mapping and Sequencing Data. NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Development of a Benchtop Laboratory Platform for Amplicon Deep Sequencing. Risk Reduction Toolkit for Non-Prescription Syringe Sales in Community Pharmacies. NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD): Heat Stable Sabin-based Inactivated Polio Vaccine.2. NIH/CDC SBIR Contract Solicitation PHS 2018-1, including proposal forms, will be available electronically on or around July 17, 2017 through the NIH Small Business Research Funding Opportunities Web site and at fedbizopps.gov. Note: The PHS 2017-2 Omnibus Solicitation of the National Institutes of Health, Centers for Disease Control and Prevention and Food and Drug Administration for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) GRANT Applications, where investigator-initiated ideas are encouraged, is open and is available at the same Web site noted above with a due dates of September 5, 2017 and January 5, 2018. To understand better the differences between grants and contracts, see https://sbir.nih.gov/apply.For general information regarding the NIH/CDC SBIR Program, please refer to:Office of Extramural Programs, Office of Extramural Research, National Institutes of HealthPhone 301-435-2688sbir@od.nih.gov
PHS-2018-1 Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases
6/29/17, 11:15 AM